UPDATE: William Blair Starts BioScrip (BIOS) at Outperform

(updating comment)

William Blair analyst Matt Larew initiates coverage on BioScrip (NASDAQ: BIOS) with a Outperform rating.

The analyst comments "Patients, payers, and providers are aligned behind the shifting hub of healthcare from the hospital into the home. As the largest independent provider of home infusion services in the United States, Option Care is well positioned to benefit as the “three Ps of healthcare” drive deeper penetration of infusion services into the home. For many patients, infusion can be performed in the home or ambulatory setting at a much lower cost than the hospital without sacrificing clinical quality—part of the reason the home infusion industry has been growing 5%-7% annually."

For an analyst ratings summary and ratings history on BioScrip click here. For more ratings news on BioScrip click here.

Shares of BioScrip closed at $3.85 yesterday.

You May Also Be Interested In

• Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
• Goldman Sachs Starts InnoScience (Suzhou) Technology (2577:HK) at Buy
• US Tiger Securities Upgrades Coinbase (COIN) to Buy